AI Article Synopsis
- In patients with non-seminomatous germ cell tumors (NSGCTs), an elevated serum marker after chemotherapy suggests active disease, leading to the use of high-dose chemotherapy (HDCT) for relapsed cases.
- A case study reports a patient whose alpha-fetoprotein levels increased after HDCT, initially indicating disease progression, but further analysis revealed no viable cancer cells in the resected tumor.
- This suggests that the elevated marker level was due to liver recovery from chemotherapy, highlighting the importance of distinguishing marker elevation from actual disease progression in managing relapsed NSGCT patients.
Article Abstract
In patients with non-seminomatous germ cell tumours (NSGCTs) who receive chemotherapy and have residual disease, a persistently elevated serum marker level after induction chemotherapy indicates active and progressive disease. High-dose chemotherapy (HDCT) is the standard treatment for patients with relapsed NSGCT. We present a case of a patient with residual disease from NSGCT who showed an increase in serum alpha-fetoprotein levels after HDCT, mimicking progression. Resection of the mass did not show viable cells in the tumour specimen, thus suggesting that the elevated level of the marker was expression of hepatic reconstitution after drug-induced liver damage. HDCT is increasingly used in cases of relapsed NSGCT, and the possibility of treatment-induced alpha-fetoprotein elevation must be taken into account in patient management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1179/1973947812Y.0000000044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Amyloid-plaque removal by monoclonal antibody therapies slows progression in symptomatic Alzheimer's disease (AD), but effects on preventing the onset of symptoms and dementia in asymptomatic people with amyloid plaques are unknown. We report the final primary and secondary outcomes of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial to evaluate amyloid-plaque removal in delaying disease progression, including symptom onset, in symptomatic and asymptomatic dominantly inherited Alzheimer's disease (DIAD) individuals treated for up to a decade.
Method: This double-blind, phase 2/3 trial (2012-2019), followed by open-label extension (OLE), investigated varying gantenerumab doses up to 1500 mg subcutaneous q2 weeks [NCT01760005].
Developing Topics.
Alzheimers Dement
December 2024
Knight Alzheimer Disease Research Center, St. Louis, MO, USA.
Background: Amyloid-related Imaging Abnormalities (ARIA) are side effects of beta-amyloid plaque-lowering monoclonal antibody drugs (APLmAbs). Understanding of ARIA mechanisms, risks, nature, evolution and optimal approaches to mitigation and management remains incomplete. Sporadic Alzheimer's Disease (AD) trials support ARIA risk factors including higher APLmAb doses/exposures, ApoE4-carrier status, and presence/severity of microhemorrhages (MCH)/superficial siderosis.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Washington University in St. Louis, St. Louis, MO, USA.
Background: Anti-amyloid monoclonal antibody therapies for AD have documented plaque removal on amyloid PET scans. We evaluate the findings for amyloid PET, tau PET, FDG PET and volumetric MRI over the course the open label extension (OLE) for the DIAN-TU gantenerumab treatment, compared to the last imaging obtained prior to the OLE (to evaluate for potential rebound effects) and in comparison to longitudinal imaging in the DIAN Observational study.
Method: This double-blind, phase 2/3 trial (2012-2019), followed by open-label extension (OLE), investigated varying gantenerumab doses up to 1500 mg SQ q2 weeks [NCT NCT01760005].
Developing Topics.
Alzheimers Dement
December 2024
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Background: BACE inhibitors, while effective in lowering amyloid-beta production, have been associated with mild cognitive worsening in clinical trials. Additional treatment-related adverse events reported in multiple clinical trials were sleep disturbances and insomnia. The purpose of this study is to determine if sleep disturbances occur in mice receiving BACE inhibitor, if sleep disturbances correlate with cognitive impairment, and the mechanism by which this may occur.
View Article and Find Full Text PDFBackground: Harmful care including the prescribing of high-risk and potentially inappropriate medications for older people is widespread among older adults, including people living with dementia (PLWD). Integrated Memory Care (IMC) is a comprehensive dementia care model where patients and their family caregivers access dementia-sensitive geriatric primary care.
Methods: We conducted a retrospective observational study of adult patients of IMC, Cognitive Neurology (CN), and Primary Care (PC) clinics aged 65 and older with a diagnosis of dementia in 2019-2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!